Oxymetholone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Oxymetholone
| |
| Systematic (IUPAC) name | |
| 17β-hydroxy-2-hydroxymethylene- 17α-methyl-3-androstanone | |
| Identifiers | |
| CAS number | |
| ATC code | A14 |
| PubChem | |
| Chemical data | |
| Formula | C21H32O3 |
| Mol. mass | 332.48 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Metabolism | Hepatic |
| Half life | 8-9 hours |
| Excretion | Urinary:95% |
| Therapeutic considerations | |
| Pregnancy cat. |
X |
| Legal status |
Prescription only |
| Routes | Oral |
|
WikiDoc Resources for Oxymetholone | |
|
Articles | |
|---|---|
|
Most recent articles on Oxymetholone Most cited articles on Oxymetholone | |
|
Media | |
|
Powerpoint slides on Oxymetholone | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Oxymetholone at Clinical Trials.gov Clinical Trials on Oxymetholone at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Oxymetholone
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Oxymetholone Discussion groups on Oxymetholone Patient Handouts on Oxymetholone Directions to Hospitals Treating Oxymetholone Risk calculators and risk factors for Oxymetholone
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Oxymetholone | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Oxymetholone (Anadrol), is a synthetic anabolic steroid developed by Syntex in 1960. Its primary clinical applications include treatment of osteoporosis and anaemia, as well as stimulating muscle growth in undernourished or underdeveloped patients. The drug was approved for human use by the FDA. However, later non-steroidal drugs such as Epogen were developed and proven to be more effective as a treatment for anaemia and osteoporosis without the side-effects of oxymetholone. The drug remained available despite this, and eventually found a new use in treating HIV wasting syndrome. While classified as a Schedule III drug under the Controlled Substances Act, it remains available via prescription as Anadrol®-50. Anadrol®-50 is a registered trademark of Alaven™ Pharmaceutical.
Presented most commonly as a 50 mg tablet, Oxymetholone is the strongest androgenic steroid available. Similarly, it also poses the greatest risk of side effects of any steroid. Despite very low binding affinity with the androgen receptor, oxymetholone is highly effective in promoting extensive gains in body mass, mostly by greatly improving protein synthesis. For this reason, it is often used illegally by bodybuilders and athletes. Many athletes also use Oxymetholone as a method of protection for the joints under heavy loads. Due to the high water retention users experience from this drug, it similarly lubricates the joints and helps protect them from injury. Oxymetholone is widely considered by bodybuilders to have the strongest anabolic effect out of any oral steroid available; weight increases of 20 pounds in 2 weeks are not unheard of with this drug.
Side effects
The side-effects of short-term use of the drug itself include nausea, bloating, acne, and masculinising effects such as deepening of the voice, growth of facial hair and clitoral hypertrophy . In addition, oxymetholone is readily aromatized by aromatase to form a progestagen, and unless selective estrogen receptor modulators such as tamoxifen or clomifene are taken in conjunction with the drug, there is a significant risk of the appearance of estrogenic effects such as gynaecomastia over time. Because of its 17α-alkylated structure, oxymetholone is highly hepatotoxic. Long term use of the drug can cause a variety of serious ailments, including hepatitis, liver cancer, and cirrhosis. It's dangerous to take oxymetholone in high dosages for periods of time exceeding four weeks, and is commonly used by bodybuilders during the start of a steroid cycle to help gain mass and increase serum levels of androgens quickly.
Use with other steroids
To further increase its effectiveness as an anabolic agent, bodybuilders typically stack (see steroid stack) oxymetholone with other anabolic steroids. Since it is already a very potent androgen, many users will combine it with drugs such as nandrolone, boldenone and testosterone to further their gains.
References
External links
- Information about Oxymetholone/Anadrol used as an anabolic steroid
- Oxymetholone information at Rxlist.com
Anabolic steroids (A14) (trademark names in brackets) | |
|---|---|
| Androstan (carbon 19 present) | Androstadienone • Boldenone undecylenate (Equipoise) • 4-Chlordehydromethyltestosterone (Turinabol) • Clostebol • Desoxymethyltestosterone (Madol) • DHEA • DHT • Drostanolone (Masteron) • Fluoxymesterone (Halotestin) • Furazabol (Miotolan) • Methandrostenolone (Dianabol) • Methenolone • Mesterolone (Proviron) • Methenolone enanthate (Primobolan) • Mestanolone • Norethandrolone • Oxandrolone (Anavar) • Oxymetholone (Anadrol) • Oxymetholone (Anadrol-50) • Quinbolone (Anabolicum Vister) • Stanozolol (Winstrol) • Testosterone |
| Estren (carbon 19 absent) | Ethylestrenol • Mibolerone (Cheque Drops) • Nandrolone (Deca Durabolin) • Norbolethone (Genabol) • Oxabolone cipionate • Tetrahydrogestrinone (The Clear) • Trenbolone (Fina) |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
